The KRAS G12C mutation, involving a glycine-to-cysteine substitution, is particularly significant in non-small-cell lung cancer, where it leads to persistent activation of the KRAS oncogenic pathway, driving uncontrolled cell growth [44]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.